title: Vasopressin analogues and V1a receptor agonists in septic shock.
abstract: This article reviews the role of arginine-vasopressin and the vasopressin analogue terlipressin as potent alternative vasoconstrictors in the treatment of fluid and catecholamine-refractory septic shock. Terlipressin is the most selective, clinically available V1 receptor agonist, and may be more potent than arginine-vasopressin in restoring catecholamine refractory septic shock. Recent experimental and clinical studies on terlipressin, as well as the possible benefit of selective V1a receptor agonists, are discussed.
authors.forename: Marc O
authors.initials: MO
authors.lastname: Maybauer
authors.forename: Dirk M
authors.initials: DM
authors.lastname: Maybauer
mesh_terms: D001127:Arginine Vasopressin / Q000737:chemistry / Q000494:pharmacology*; D002395:Catecholamines / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D008236:Lypressin / Q000031:analogs & derivatives / Q000494:pharmacology; D008833:Microcirculation; D010477:Perfusion; D017483:Receptors, Vasopressin / Q000819:agonists*; D012772:Shock, Septic / Q000188:drug therapy*; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
chemical_list: D002395:Catecholamines; D017483:Receptors, Vasopressin; D014662:Vasoconstrictor Agents; D001127:Arginine Vasopressin; D008236:Lypressin; D000077585:Terlipressin